Aswini Saravanan

Aswini Saravanan

Auto-generated profile, based on publicly available information

Aswini Saravanan

Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, India

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2024 in eClinicalMedicine
Verified
Journal Article
Open access
MSMuhammad Aaqib Shamim
Muhammad Aaqib Shamim
JKJogender Kumar
Jogender Kumar
APAmol N Patil
Amol N Patil
KTKrishna Tiwari
Krishna Tiwari
SSSakshi Sharma
Sakshi Sharma
PDPradeep Dwivedi
Pradeep Dwivedi
Initial randomised controlled trials (RCTs) showed that prophylactic azithromycin in pregnant women improved maternal and neonatal outcomes; however, the recent evidence did not show any benefit to neonatal survival. There is conflicting evidence over the role of azithromycin prophylaxis in antenatal and intrapartum periods. We explored whether azithromycin prophylaxis in pregnant women improves maternal and neonatal outcomes. For this systematic review and meta-analysis registered on PROSPERO [CRD42023411093], we searched seven databases (PubMed, Scopus, Embase, Cochrane Library, EBSCOHost, ProQuest, and Web of Science) and clinical trial registries until 04/23/2024, for RCTs evaluating antenatal/intrapartum azithromycin prophylaxis against placebo/routine care in pregnant women. The primary outcome was neonatal mortality. Intrapartum and antenatal administration were assessed separately. We used random-effects meta-analysis. The risk of bias was assessed using the Cochrane RoB 2 tool. The GRADE approach was used to evaluate the certainty of the evidence. Screening 2161 records retrieved 20 RCTs (56,381 participants). Intrapartum azithromycin may make little or no difference to neonatal mortality [5 RCTs, 44,436 participants; Risk Ratio (RR): 1.02, 95% CI 0.86-1.20, I 2 = 0%, very low certainty], and maternal mortality [3 RCTs, 44,131 participants, RR: 1.26, 0.65-2.42, I 2 = 0%, low certainty]. Similarly, antenatal azithromycin may have little or no effect on neonatal mortality [3 RCTs; 5304 participants; RR: 0.74, 0.35-1.56, I 2 = 43%, very-low certainty] and maternal mortality [3 RCTs; 8167 participants RR: 1.62, 0.67-3.91, I 2 = 0%, low certainty]. There is no data on long-term adverse outcomes and antimicrobial resistance. Low to very low certainty evidence suggests that intrapartum or antenatal azithromycin prophylaxis in pregnant women might not reduce maternal or neonatal mortality. None.

24 August 2023 in Heliyon
Verified
Journal Article
Open access
AAAbhishek Anil
Abhishek Anil
ASAswini Saravanan
Aswini Saravanan
SSSurjit Singh
Surjit Singh
MSMuhammad Aaqib Shamim
Muhammad Aaqib Shamim
KTKrishna Tiwari
Krishna Tiwari
Ranjit SahRanjit Sah
Ranjit Sah
The increasing pressure to publish research has led to a rise in plagiarism incidents, creating a need for effective plagiarism detection software. The importance of this study lies in the high cost variation amongst the available options for plagiarism detection. By uncovering the advantages of these low-cost or free alternatives, researchers could access the appropriate tools for plagiarism detection. This is the first study to compare four plagiarism detection tools and assess factors impacting their effectiveness in identifying plagiarism in AI-generated articles. A prospective cross-over study was conducted with the primary objective to compare Overall Similarity Index(OSI) of four plagiarism detection software(iThenticate, Grammarly, Small SEO Tools, and DupliChecker) on AI-generated articles. ChatGPT was used to generate 100 articles, ten from each of ten general domains affecting various aspects of life. These were run through four software, recording the OSI. Flesch Reading Ease Score(FRES), Gunning Fog Index(GFI), and Flesch-Kincaid Grade Level(FKGL) were used to assess how factors, such as article length and language complexity, impact plagiarism detection. The study found significant variation in OSI(p < 0.001) among the four software, with Grammarly having the highest mean rank(3.56) and Small SEO Tools having the lowest(1.67). Pairwise analyses revealed significant differences(p < 0.001) between all pairs except for Small SEO Tools-DupliChecker. Number of words showed a significant correlation with OSI for iThenticate(p < 0.05) but not for the other three. FRES had a positive correlation, and GFI had a negative correlation with OSI by DupliChecker. FKGL negatively correlated with OSI by Small SEO Tools and DupliChecker. Grammarly is unexpectedly most effective in detecting plagiarism in AI-generated articles compared to the other tools. This could be due to different softwares using diverse data sources. This highlights the potential for lower-cost plagiarism detection tools to be utilized by researchers.

10 November 2023 in Medicine
Verified
Journal Article
Open access
SMSubhanwita Manna
Subhanwita Manna
PDPradeep Dwivedi
Pradeep Dwivedi
MSMukesh Kumar Swami
Mukesh Kumar Swami
SSSwapnajeet Sahoo
Swapnajeet Sahoo
RSRavindra Dm Shukla
Ravindra Dm Shukla
Ranjit SahRanjit Sah
Ranjit Sah
Background: Major depressive disorder is often resistant to first-line treatment, with around 30% failing to respond to traditional therapy. Treatment-resistant depression results in prolonged hospitalization and healthcare costs. Anti-inflammatory drugs have shown promising results in depression not responding to initial therapy. Minocycline has anti-inflammatory properties and crosses the blood-brain barrier. It has demonstrated varied results in several randomized controlled trials (RCTs). Methods: We assessed the efficacy of minocycline compared to placebo in depression not responding to one first-line antidepressant via a systematic review and meta-analysis. We performed a comprehensive literature search across PubMed, Cochrane, and Scopus for RCTs. We visualized the results using forest plots and drapery plots. We assessed and explored heterogeneity using I 2, prediction interval, and meta-regression. Then, we rated the certainty of the evidence. Results: Four RCTs revealed a non-significant difference in depression severity [−3.93; 95% CI: −16.14 to 8.28], rate of response [1.15; 0.33–4.01], and rate of remission [0.94; 0.44–2.01]. However, the reduction in depression severity is significant at a trend of P < .1. The high between-study heterogeneity (I 2 = 78%) for depression severity could be answered by meta-regression (P = .02) for the duration of therapy. Conclusion: There is no significant difference with minocycline compared to placebo for depression not responding to first-line antidepressant therapy. However, the treatment response varies with treatment duration and patients’ neuroinflammatory state. Thus, larger and longer RCTs, especially in diverse disease subgroups, are needed for further insight. This is needed to allow greater precision medicine in depression and avoid elevated healthcare expenditure associated with hit-and-trial regimens. Registration: CRD42023398476 (PROSPERO).

24 October 2024 in International Journal of Dermatology
Verified
Journal Article
Closed access
ASAswini Saravanan
Aswini Saravanan
AAAbhishek Anil
Abhishek Anil
ABAbhishek Bhardwaj
Abhishek Bhardwaj
RSRavindra Shukla
Ravindra Shukla
NBNitin Kumar Bajpai
Nitin Kumar Bajpai
SVShoban Babu Varthya
Shoban Babu Varthya

21 April 2024 in World Neurosurgery
Verified
Journal Article
Closed access
MPMamta Patel
Mamta Patel
AMAmit K. Mittal
Amit K. Mittal
VJVibha Joshi
Vibha Joshi
MAMohit Agrawal
Mohit Agrawal
SVShoban Babu Varthya
Shoban Babu Varthya
KSKuldeep Singh
Kuldeep Singh

4 June 2024 in BMJ Open
Verified
Journal Article
Open access
PDF file
MSMuhammad Aaqib Shamim
Muhammad Aaqib Shamim
RSRavindra Shukla
Ravindra Shukla
MSMukesh Kumar Swami
Mukesh Kumar Swami
SSShival Srivastav
Shival Srivastav
APAnindita Pradhan
Anindita Pradhan
PDPradeep Dwivedi
Pradeep Dwivedi
Introduction Diabetes and depression are among the 10 biggest health burdens globally. They often coexist and exhibit a strong bidirectional relationship. Depression leads to decreased adherence to self-care activities. This impacts glycaemic control and worsens type 2 diabetes mellitus (T2D). Both conditions have a synergistic effect and lead to greater complications, hospitalisations, healthcare expenditure and a worse quality of life. There is no consensus on managing people with comorbid T2D and depression. Bupropion is an efficacious antidepressant with many properties suitable for T2D with depression, including a favourable metabolic profile, persistent weight loss and improvement in sexual dysfunction. We will assess the efficacy and safety of add-on bupropion compared with standard care in people with T2D and mild depression. This study can give valuable insights into managing the multimorbidity of T2D and depression. This can help mitigate the health, social and economic burden of both these diseases. Research design and methods This cross-over randomised controlled trial will recruit people with T2D (for 5 years or more) with mild depression. They will be randomised to add-on bupropion and standard care. After 3 months of treatment, there will be a washout period of 1 month (without add-on bupropion while standard treatment will continue). Following this, the two arms will be swapped. Participants will be assessed for glycosylated haemoglobin, adherence to diabetes self-care activities, lipid profile, urine albumin-to-creatinine ratio, autonomic function, sexual function, quality of life and adverse events. Ethics and dissemination The Institutional Ethics Committee at All India Institute of Medical Sciences, Jodhpur has approved this study (AIIMS/IEC/2022/4172, 19 September 2022). We plan to disseminate the research findings via closed group discussions at the site of study, scientific conferences, peer-reviewed published manuscripts and social media. Trial registration number CTRI/2022/10/046411.